Aurobindo Pharma is currently trading at Rs. 174.30, up by 13.25 points or 8.23% from its previous closing of Rs. 161.05 on the BSE.
The scrip opened at Rs. 166.15 and has touched a high and low of Rs. 176.65 and Rs. 166.15 respectively. So far 283761 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 204.90 on 03-Jan-2013 and a 52 week low of Rs. 99.65 on 10-Aug-2012.
Last one week high and low of the scrip stood at Rs. 176.65 and Rs. 138.45 respectively. The current market cap of the company is Rs. 5023.39 crore.
The promoters holding in the company stood at 54.84% while Institutions and Non-Institutions held 31.65% and 13.51% respectively.
Aurobindo Pharma has received its board’s approval to acquire 60% of an upcoming manufacturing facility (under construction) being established by Celon Laboratories to manufacture Hormonal and Oncology products for a total cash consideration of Rs 15.60 crore and also approved to further invest towards completion and approval of the facility including new product developments in above therapeutic areas with budgeted investment outlay of Rs 32.30 crore over next 12 months
Meanwhile, the company’s board has decided to acquire 57% of the equity stake in Silicon Life Sciences Private, a company engaged in manufacture of non-sterile penems, from its existing shareholders of 49% from VVR group and 8% from Trident Chemphar. Post this acquisition, the equity holding of the company would increase to 75%, thereby making Silicon a subsidiary of the company.
Aurobindo Pharma manufactures generic pharmaceuticals and active pharmaceutical ingredients. The company’s robust product portfolio is spread over 6 major therapeutic/product areas encompassing Antibiotics, Anti-Retrovirals, CVS, CNS, Gastroenterologicals, and Anti-Allergics, supported by an outstanding R&D set-up.
The scrip opened at Rs. 166.15 and has touched a high and low of Rs. 176.65 and Rs. 166.15 respectively. So far 283761 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 204.90 on 03-Jan-2013 and a 52 week low of Rs. 99.65 on 10-Aug-2012.
Last one week high and low of the scrip stood at Rs. 176.65 and Rs. 138.45 respectively. The current market cap of the company is Rs. 5023.39 crore.
The promoters holding in the company stood at 54.84% while Institutions and Non-Institutions held 31.65% and 13.51% respectively.
Aurobindo Pharma has received its board’s approval to acquire 60% of an upcoming manufacturing facility (under construction) being established by Celon Laboratories to manufacture Hormonal and Oncology products for a total cash consideration of Rs 15.60 crore and also approved to further invest towards completion and approval of the facility including new product developments in above therapeutic areas with budgeted investment outlay of Rs 32.30 crore over next 12 months
Meanwhile, the company’s board has decided to acquire 57% of the equity stake in Silicon Life Sciences Private, a company engaged in manufacture of non-sterile penems, from its existing shareholders of 49% from VVR group and 8% from Trident Chemphar. Post this acquisition, the equity holding of the company would increase to 75%, thereby making Silicon a subsidiary of the company.
Aurobindo Pharma manufactures generic pharmaceuticals and active pharmaceutical ingredients. The company’s robust product portfolio is spread over 6 major therapeutic/product areas encompassing Antibiotics, Anti-Retrovirals, CVS, CNS, Gastroenterologicals, and Anti-Allergics, supported by an outstanding R&D set-up.
No comments:
Post a Comment